{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:45:41Z","timestamp":1795041941928,"version":"4.10.2"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128236","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:26:02Z","timestamp":1769113562000},"page":"128236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials"],"prefix":"10.1016","volume":"75","author":[{"given":"Joanne M.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis L.","family":"Breeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Feser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Hosken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indah","family":"Andi-Lolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil A.","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128236_bb0015","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1093\/infdis\/jiaa535","article-title":"Triumph of pneumococcal conjugate vaccines: overcoming a common foe","volume":"224","author":"Rodgers","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0020","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.05002","volume":"13","author":"Reyburn","year":"2023","journal-title":"J Glob Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128236_bb0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128236_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.GPP3-0004-2018","article-title":"Streptococcus pneumoniae: invasion and inflammation","volume":"7","author":"Loughran","year":"2019","journal-title":"Microbiol Spectr"},{"issue":"400","key":"10.1016\/j.vaccine.2026.128236_bb0035","first-page":"2221","article-title":"Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: A systematic analysis for the global burden of disease study 2019","volume":"2022","author":"GBD","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128236_bb0040","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"L\u00f8chen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128236_bb0045","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1080\/21645515.2021.1985353","article-title":"Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines","volume":"17","author":"Du","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128236_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032134","article-title":"Streptococcus pneumoniae serotype-2 childhood meningitis in Bangladesh: a newly recognized pneumococcal infection threat","volume":"7","author":"Saha","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128236_bb0055","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1097\/INF.0000000000001067","article-title":"Pediatric invasive pneumococcal disease in Guatemala City: importance of serotype 2","volume":"35","author":"Gaensbauer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128236_bb0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/JCM.01984-08","article-title":"Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae","volume":"47","author":"Nunes","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.128236_bb0065","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0070","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.50.30423","article-title":"Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014","volume":"21","author":"Sheppard","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128236_bb0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3201\/eid2402.171268","article-title":"Spread of meropenem-resistant Streptococcus pneumoniae serotype 15A-ST63 clone in Japan, 2012-2014","volume":"24","author":"Nakano","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0080","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.vaccine.2006.09.016","article-title":"Molecular characterisation of pneumococcal serotype 16F: established predominant carriage and otitis media serotype in the 7vPCV era","volume":"25","author":"Marsh","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128236_bb0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1473-3099(18)30349-9","article-title":"Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey","volume":"18","author":"Ouldali","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0090","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","article-title":"Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study","volume":"3","author":"Lo","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128236_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3201\/eid2402.170982","article-title":"Invasive serotype 35B pneumococci including an expanding serotype switch lineage","volume":"24","author":"Olarte","year":"2018","journal-title":"Emerging Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Quesada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2010.10.032","article-title":"Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease","volume":"29","author":"Yildirim","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128236_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2117949","article-title":"Multi-valent pneumococcal conjugate vaccine for global health: from problem to platform to production","volume":"18","author":"Datta","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128236_bb0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128236_bb0120","series-title":"Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"Food and Drug Administration","year":"2007"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128236_bb0125","first-page":"514","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2026.128236_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128236_bb0135","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.vaccine.2026.128236_bb0145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00086-12","article-title":"Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20","volume":"19","author":"Burton","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128236_bb0150","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Inf Dis J"},{"key":"10.1016\/j.vaccine.2026.128236_bb0155","doi-asserted-by":"crossref","unstructured":"Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013;9:2505\u201323. https:\/\/doi:https:\/\/doi.org\/10.4161\/hv.26109.","DOI":"10.4161\/hv.26109"},{"key":"10.1016\/j.vaccine.2026.128236_bb0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41479-017-0030-5","article-title":"Pneumococcal conjugate vaccine implementation in middle-income countries","volume":"9","author":"Tricarico","year":"2017","journal-title":"Pneumonia (Nathan)"},{"key":"10.1016\/j.vaccine.2026.128236_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1031924","article-title":"The adaptive immune system in early life: the shift makes it count","volume":"13","author":"Pieren","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128236_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2023.10.043","article-title":"A quantitative clinical pharmacology-based framework for model-informed vaccine development","volume":"113","author":"Desikan","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2026.128236_bb0175","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1016\/j.vaccine.2014.05.008","article-title":"Challenges in vaccination of neonates, infants and young children","volume":"32","author":"Pichichero","year":"2014","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128236_bb0180","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/cid\/ciac302","article-title":"Precision vaccine adjuvants for older adults: a scoping review","volume":"75","author":"Nanishi","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:48:57Z","timestamp":1772552937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"alternative-id":["S0264410X26000435"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128236","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128236"}}